Poor spatial resolution of current imaging modalities often limits monitoring of both angiogenesis and outcome of vascular-targeted therapies. So far, a detailed evaluation has only been possible using invasive approaches. RSOM (raster-scanning optoacoustic mesoscopy) takes advantage of the intrinsic optical properties of hemoglobin, high-frequency laser illumination, and detection of a broad ultrasound bandwidth. This provides non-invasive, high-resolution images of differentsized tumor vessels and facilitates detailed insights into dynamic responses to novel vascular-targeted therapies.
